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ABSTRACT
Objectives: Accelerated intermittent theta burst stimulation (aiTBS) is a promising treatment option for depressed patients. However,
there is a large interindividual variability in clinical effectiveness and individual biomarkers to guide treatment outcome are needed.
Materials and Methods: Here, the relation between cortical thickness and clinical response (17-item Hamilton Depression Rat-
ing Scale) was studied using anatomical MRI data of 50 depressed patients who were included in a randomized, sham-con-
trolled, double-blinded, cross-over aiTBS design (NCT01832805).
Results: Baseline cortical thickness in the right caudal part of the anterior cingulate cortex (cACC) was significantly correlated
with direct clinical responses in the subgroup who received active aiTBS during the first stimulation week. No correlations
were found between baseline cortical thickness and delayed clinical effectiveness. In this particular region, longitudinal
changes in cortical thickness were significantly correlated with clinical effectiveness. Furthermore, direct changes in cortical
thickness in the right cACC showed predictive potential of delayed clinical responses.
Conclusion: Cortical thickness within the right cACC might be an important biomarker to predict clinical responses to aiTBS.
Additional studies are warranted to substantiate the specific biomarker potential of these parts of the ACC.
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INTRODUCTION
Major depressive disorder (MDD) is one of the most prevalent psy-
chiatric disorders affecting more than 264 million people worldwide
(1). Despite the availability of multiple therapeutic interventions, such
as psychotherapy and pharmacotherapy, approximately one-third of
the subjects will not respond to these available interventions and
will develop treatment resistant depression (TRD).
Repetitive transcranial magnetic stimulation (rTMS) is a nonin-
vasive brain stimulation technique that is approved for the treat-
ment of TRD by the U.S. food and drug administration (FDA). The
most standard stimulation protocol for TRD treatment contains
daily high-frequency (>10 Hz, presumably excitatory) stimulation
sessions targeting the left dorsolateral prefrontal cortex (DLPFC)
with a figure-of-eight shaped coil for a period of four to six weeks
(2,3). Less time-consuming accelerated rTMS protocols, that is,
applying multiple stimulation sessions a day over a shorter period
of time, are under investigation but not FDA approved yet (4). A
particular rTMS design, intermittent theta burst stimulation (iTBS
(5)) administered to the left DLPFC has shown promising thera-
peutic outcome for depression patients and mostly showed to be
beneficial in terms of duration and it can be applied at a lower
stimulation intensity (6). In our laboratory, an accelerated iTBS
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(aiTBS) protocol, in which five daily iTBS sessions were adminis-
tered on four consecutive days, was investigated as treatment for
TRD patients (7). Two weeks after the end of the randomized
double-blind, sham-controlled, stimulation design, a response rate
of 38% was observed, indicating delayed clinical effects. Of these
responders, 30% were in remission.
Notwithstanding, the overall response rates of any rTMS treat-
ment protocol are still rather modest. The high interindividual
heterogeneity of clinical effectiveness underscores the pressing
need for biomarkers to predict treatment outcome. Previous stud-
ies showed promising results using measures derived from
resting-state functional MRI (rs-fMRI) (8–10) or diffusion weighted
MRI (dMRI) (11). However, these biomarkers require extensive
imaging protocols that are not always available in clinical settings,
need specialized data processing, and are costly. Therefore, sim-
pler biomarkers, for example, cortical thickness (CT) measures, as
derived from anatomical MRI data, could be more feasible.
Indeed, cortical thickness has shown to be a sensitive biomarker
for a wide variety of neuropsychiatric diseases, including MDD
(12–14). Moreover, Boes et al. (15) showed that baseline
(i.e., before stimulation) thickness is related to clinical response to
a four to six weeks rTMS protocol in MDD patients targeting the
left DLPFC. Specifically, it was shown that smaller baseline cortical
thickness in the left rostral anterior cingulate cortex (rACC) could
predict better clinical response, that is, greater improvement of
depressive symptoms. Furthermore, thickness of the rACC was
shown to increase in responding patients.
In this aiTBS study including MDD patients documented to be
resistant to at least one psychotropic intervention, we retrospec-
tively investigated whether cortical thickness could be related to
clinical response. In line with the previous findings from Boes
et al. (15), it was hypothesized that especially the cortical thick-
ness in parts of the cingulate cortex would play a pivotal role in
the treatment efficacy of aiTBS. Different parts of the cingulate
cortex are involved in different functions. More specifically, the
anterior part (ACC) belongs to the limbic system and is involved in
the regulation of cognitive and emotional processing (16). For exam-
ple, greater functional activity was found in the rostral ACC in medi-
tators compared to healthy controls, which might reflect stronger
processing of distracting events (17). Functional connectivity
between the subgenual part of the ACC and the stimulation site in
the left DLPFC (8,18) and indirect structural connections between
the DLPFC and the caudal part of the ACC (11) were previously
related to the effectiveness of rTMS treatment for depression.
MATERIALS AND METHODS
This registered RCT (http://clinicaltrials.gov/show/NCT01832805)
was approved by the ethics committee of Ghent University Hospi-
tal and was conducted in line with the declaration of Helsinki.
Written informed consent was obtained from all patients prior to
participation.
Inclusion
For this RCT, 50 right-handed patients with TRD (mean age
42 years, SD 12 years) were recruited from the Ghent University
Hospital. MDD was diagnosed using the structured diagnostic psy-
chiatric Mini-International Neuropsychiatric Interview (MINI (19)).
Patients were only included if treatment resistance was at least
stage I (i.e., nonresponse to at least one trial with serotonin-
reuptake inhibitors or noradrenaline/serotonin-reuptake inhibi-
tors). More detailed information can be found in Duprat et al. (7).
Study Design
The overall design of this randomized, sham-controlled,
double-blinded, cross-over trial is depicted in Fig. 1. In short, prior
2
Figure 1. Overall design of this randomized, sham-controlled, double-blinded, cross-over trial. Adapted from Duprat et al. (7).
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to the start of the study, patients underwent a two-week wash-
out period followed by a two-week antidepressant free period.
Patients were randomized to receive first sham aiTBS followed by
active aiTBS (arm A in Fig. 1) or the other way around (arm B in
Fig. 1). On the first day (T1), a 3 T Siemens TrioTim scanner
(Erlangen, Germany) was used to record anatomical MRI data
(MPRAGE, TR = 2530 msec, TE = 2.58 msec, FA = 7 ,
FOV = 220 × 220 mm2, resolution = 0.9 × 0.9 × 0.9 mm3,
176 slices). On the 8th day (T2) and the 15th day (T3), the MRI
acquisition protocol was repeated.
On days 2–5 (week 1) and days 9–12 (week 2), active or sham
aiTBS was applied depending on the randomization order. A Mag-
stim Rapid2 Plus1 magnetic stimulator (Magstim Company Limited,
Wales, UK) connected to an active or sham figure-of-eight shaped
coil (Magstim 70 mm double air film [sham] coil) was used to apply
the active and sham stimulation, respectively. One iTBS session con-
sisted of 54 trains containing ten bursts of three stimuli at 50 Hz,
repeated every 200 msec, alternated by six seconds rest. According
to the accelerated protocol, five daily stimulation sessions were
given with 15 min rest in between on four consecutive days.
Depression severity was assessed with the Hamilton Depression
Rating Scale (HDRS (20)) directly after randomization (baseline,
T1), after the first stimulation week (T2), at the end of the second
stimulation week (T3) and two weeks following the end of stimu-
lation during follow-up (T4).
Baseline Cortical Thickness vs. Clinical Effectiveness of aiTBS
Data Driven Whole Brain Analysis
Freesurfer 6.0 (http://surfer.nmr.mgh.harvard.edu) was used to
perform cortical reconstruction of all baseline (T1) MPRAGE
data (21). Using the optimized recon-all command, automatic
brain parcellation was performed including the delineation of the
white and pial surface such that cortical thickness could be
defined over all vertices. Freesurfer parcellation of the white and
pial surfaces for each patient was reviewed manually. For this sur-
face group analysis, a smoothing kernel of 15 mm (FWHM) was
used to map the individual data to the fsaverage template (in line
with Boes et al. (15)).
Because of the cross-over design of the study, a distinction was
made between the prediction of the direct clinical effects, defined
as ΔHDRSdir (= −(HDRST2-HDRST1)) and the delayed clinical effects
(ΔHDRSdel = −(HDRST4-HDRST1)). A general linear model fitting
method, as implemented in query, design, estimate, contrast
(QDEC), was used to study the correlations between cortical thick-
ness in every vertex and the clinical effects, thereby correcting for
the baseline (T1) HDRS scores. Additionally, correction for order
(i.e., sham or active aiTBS) was performed for the prediction of
the direct effects. A statistical threshold of p < 0.001 uncorrected
was selected for the analysis (15). Therefore, this analysis is pre-
sumed to be exploratory.
To study the order effects in more detail, two separate analyses
were performed including only the subset of subjects receiving
sham or active aiTBS during the first week, respectively. Addition-
ally, a sub-analysis was performed on the subjects who received
active aiTBS after sham stimulation (arm A, T2 vs. T3). To compen-
sate for the loss of statistical power, statistical threshold was set
to p < 0.01.
Significant ROI Analysis
Significant ROIs were defined as the vertices in the brain with
p < 0.001 extended with the neighboring vertices with p < 0.01
(for the separate order effects these thresholds were set to
p < 0.01 with neighboring vertices p < 0.05). These were studied
in more detail on the individual level by extracting average statis-
tical information representing the total region of interest (ROI). To
that aim, the group level ROIs were mapped to the individual data
and the cortical thickness of every ROI was computed as the aver-
age of the vertices within the ROI.
Additionally, we investigated the power of the baseline cortical
thickness values of these ROIs to predict the direct and delayed
clinical responder rates (defined as >50% decrease in HDRS
scores) by means of ROC curves.
Effects of aiTBS on Cortical Thickness vs. Clinical Effectiveness
Data Driven Whole Brain Analysis
The longitudinal processing stream of Freesurfer was used to
optimize detection of changes in cortical thickness of the same
individual across two time points (22). Since no MRI data were
available at our long-term follow-up (T4), this analysis was
restricted to the direct clinical effects and hence the anatomical
MRI data of T1 and T2 were used. Similar as for the previous anal-
ysis (i.e., baseline cortical thickness versus clinical effectiveness), a
general linear model fitting method, as implemented in QDEC,
was used to study the correlations between percentage change in
cortical thickness (ΔCT %½ = CTT2−CTT1CTT1 × 100%) in every vertex and
the clinical effects, thereby correcting for the baseline (T1) HDRS
scores and for the order (i.e., sham or active aiTBS). A similar
smoothing kernel and the same statistical thresholds were used
to study significant ROIs in more detail.
Significant ROI Analysis
Significantly ROIs were defined according to the same method
as described for the first analysis of this study (i.e., “Baseline corti-
cal thickness versus clinical effectiveness of aiTBS”) and analyzed
on an individual level accordingly. Additionally, ROC curves were
computed for the prediction of the delayed clinical effects, based
on the direct effects of aiTBS on cortical thickness, using the sub-
group of patients receiving active aiTBS during the first
stimulation week.
Assessment of Confounding Factors
Previous work showed that cortical thickness could be related
to age and gender (23–26). Therefore, age and gender were
assessed as a potential confounding factors. Additionally, also the
relation between the duration of the depression episodes and the
stage of the depression and thickness were investigated. To that
aim, correlations were computed between the continuous vari-
ables (i.e., age and duration of depression episodes) and the corti-
cal thickness or the direct change in thickness in all the ROIs that
showed significant results in the two analyses. For the discrete
variables (i.e., gender and stage of the depression), two-tailed t-
tests were performed between the thickness values of the differ-
ent subgroups.
RESULTS
Biomarker Potential: Can Baseline Cortical Thickness Predict
the Clinical Response to aiTBS?
Data of 46 patients were used to study the potential of baseline
cortical thickness values to predict direct and delayed clinical
responses (one subject retrospectively received an alternative
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diagnosis and three patients dropped out before completing the
study). Of these 46 subjects, 25 received sham stimulation during
the first week (arm A) and 21 received active aiTBS (arm B). At T2
two subjects responded to stimulation, that is, showed a decrease
in HDRS score of at least 50%. After follow-up, at T4, 18 patients
showed clinical response. The results of the sub-analysis including
the patients who received active aiTBS after sham stimulation can
be found in Supporting Information A.
Prediction of Direct Clinical Effects
Figure 2 shows an overview of the significant ROIs after corre-
lating baseline cortical thickness values with ΔHDRSdir values.
In Fig. 2a, a significant ROI was found in the left superior pre-
frontal area (see Table 1 for details). This positive correlation was
found independent of the order of the stimulation sessions, that
is, if the patients received active or sham aiTBS during the first
week of stimulation. This is also depicted in Fig. 3, where the aver-
age baseline cortical thickness in the prefrontal ROI is plotted
against the clinical responses for all subjects. Positive correlations
suggest that higher baseline cortical thickness values are corre-
lated with larger clinical responses. The ROC curve is shown in
Supporting Information (A).
Of notable interest, the significant cluster in the left prefrontal
area was found to be close to the subjects’ stimulation position in
4
Figure 2. Correlations between baseline cortical thickness (CT) and direct changes in HDRS. Significant correlations between the baseline (T1) cortical thickness
and ΔHDRSdir. Figure a includes all subjects (n = 46, order corrected, dof = 40), whereas in figure b and c, results are split for the subjects receiving active aiTBS
(n = 21, dof = 18) or sham aiTBS (n = 25, dof = 22), respectively. Note the different statistical thresholds to compensate for the loss of power when studying the
subgroups. [Color figure can be viewed at wileyonlinelibrary.com]
Table 1. Detailed Information About the ROI in the Left Superior Prefrontal Cortex Showing Significant Correlation Between the Baseline CT and ΔHDRSdir.
Group level results (Fig. 2a) Individual level results (Fig. 3)
ROI Nr vertices
p < 0.001













218 529 −4.1 (152,289) −19.4 29.2 32.9 0.35, 0.02 0.37, 0.07 0.45, 0.04
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the left DLPFC. Therefore, an additional analysis was performed
based on the subject-specific stimulation position. Figure 4a
shows the individual stimulation positions (i.e., center of the stim-
ulation coil, in red). The actual brain region that is affected
extends beyond this region. To provide additional insight in the
size of the affected brain region, a simulation of the TMS-induced
electric field was added to the figure. For this simulation, an aver-
age brain was used, and the stimulation coil was positioned at
the mean coil position in our subjects (MNI -38 19 54 mm, shown
in yellow). The peak of the significant ROI (represented in green
in the figure) shows overlap with the average TMS-induced elec-
tric field distribution.
However, as can be seen in Fig. 4b, no significant correlations
were found between the baseline cortical thickness values in the
ROIs derived from the subject-specific stimulation position and
the direct clinical response (for details on methods see
Supporting Information C). The overall correlation coefficient was
−0.05 (p = 0.77) when all patients were included, and 0.02
(p = 0.94) and − 0.05 (p = 0.85) for the subgroup of patients
receiving sham and active stimulation during the first week,
respectively.
As can be seen in Fig. 1b,c, additional significant ROIs are found
when separating the data into subsets of patients who received
active (b) and sham (c) aiTBS during the first week. Specifically,
significant ROIs were found in the lateral orbitofrontal cortex
(OFC) bilaterally, left medial OFC, two different regions in the left
pars opercularis, the right caudal ACC (cACC), left posterior CC in
the subgroup of patients who received active aiTBS in the first
week. The left precuneus showed a significant correlation
between baseline cortical thickness and ΔHDRSdir in the subgroup
of patients who received sham stimulation first. Detailed informa-
tion about these ROIs is presented in Table 2. In all these ROIs, a
positive correlation was found between the baseline cortical
thickness and the direct clinical responses, that is, higher baseline
thickness is related to more clinical improvement (Fig. 5, the
corresponding ROC-curves can be found in Supporting Informa-
tion B).
Prediction of Delayed Clinical Effects
No significant correlations were found between baseline corti-
cal thickness and the delayed clinical response, ΔHDRSdel.
Mechanism of Action of aiTBS: Can Longitudinal Changes in
Cortical Thickness Be Linked to Clinical Effectiveness?
Anatomical MRI data of T1 and T2 were used to study the rela-
tion between longitudinal changes in cortical thickness and the
clinical responses. Because of insufficient MRI settings for one
5
Figure 3. Overview of the baseline (T1) cortical thickness vs. ΔHDRSdir in the
ROI in the left superior prefrontal cortex. [Color figure can be viewed at
wileyonlinelibrary.com]
Figure 4. Significant ROI in the left dorsolateral prefrontal cortex vs. individual stimulation positions. (a) Shows the position of the significant ROI in the left supe-
rior prefrontal cortex (green) with respect to the individual stimulation sites (red, mean shown in yellow). The TMS-induced electric field distribution is shown (coil
placement at the mean coil position) to provide additional insight in the spread of the TMS effects. In (b), there is no significant correlation between the baseline
cortical thickness in the individual stimulation site and the direct clinical response to aiTBS. Note that because information on the individual coil positioning was
not available for all subjects, this analysis was performed on a subset of 41 patients. [Color figure can be viewed at wileyonlinelibrary.com]
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Table 2. Detailed Information About the ROIs.




ROI (p < 0.05)
Min t-value
(vertex number)







Lateral OFC (l) 81 770 −2.522 (14,908) −24.5 35.1 −9.4 −0.26, 0.19 0.71, <0.01 0.06, 0.65
Medial OFC (l) 4 77 −2.051 (49,397) −6.5 14.6 −12.8 −0.04, 0.84 0.49, 0.02 0.15, 0.33
Pars opercularis (l,1) 514 1554 −2.982 (98,541) −32.9 11.4 11.9 −0.31, 0.13 0.57, <0.01 0.06, 0.68
Pars opercularis (l,2) 246 952 −2.816 (23,956) −44.9 6.6 14.2 −0.02, 0.93 0.74, <0.01 0.40, <0.01
Posterior CC (l) 91 315 −2.498 (10,547) −8.1 −15.0 36.2 0.12, 0.56 0.67, <0.01 0.33, 0.03
Lateral OFC (r) 82 407 −2.353 (67,779) 31.5 29.8 −10.6 −0.51, <0.01 0.54, 0.01 −0.01, 0.94
Caudal ACC (r) 2 306 −2.008 (16,032) 6.0 26.0 20.3 0.07, 0.74 0.51, 0.02 0.28, 0.06
Precuneus (l) 108 361 −2.589 (117,982) −15.1 −57.3 22.4 0.57, <0.01 0.25, 0.27 0.35, 0.02
Figure 5. Significant ROIs when splitting the analysis in subgroups who received active (n = 21) or sham (n = 25) aiTBS during the first stimulation week. [Color
figure can be viewed at wileyonlinelibrary.com]
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subject (incomplete FOV), this analysis was performed using
45 datasets.
Figure 6 shows an overview of the significant ROIs when corre-
lating ΔCT values with ΔHDRSdir values.
In Fig. 6a, a significant ROI was found in the right isthmus part
of the CC (for details see Table 3). The relation between ΔCT and
ΔHDRSdir is shown in more detail in Fig. 7.
Two additional ROIs were found when studying the subgroup
who received active aiTBS during the first week (Fig. 7b, for
details see Table 4). Positive and negative correlations were found
between ΔCT and ΔHDRSdir in the right caudal part of the ACC
and in the right precuneus area respectively. As can be seen in
Fig. 7b, the right precuneus ROI also comprises the right isthmus
part of the CC. Figure 8 shows the relation between ΔCT and
ΔHDRSdir for these two ROIs.
Of note, no significant changes in cortical thickness at the stim-
ulation site were found before and after aiTBS (see Supporting
Information C1 for more detailed information).
The direct changes in cortical thickness (T2 vs. T1) showed pre-
dictive potential for the delayed clinical effects, that is, the AUC of
the ROC curve is 0.76, in the right caudal ACC ROI in the subgroup
of patients who received active aiTBS during the first week (see
Fig. 9, n = 21, eight responders at T4).
Confounding Factors
For all the significant ROIs that were reported in this study, no
significant correlations were found between the baseline cortical
thickness and the duration of the depression, neither were statisti-
cal differences found between baseline cortical thickness in males
7
Figure 6. Significant correlations between ΔCT and ΔHDRSdir. Figure a includes all subjects (n = 45, order corrected, dof = 39) whereas in b and c, results are
split for the subjects receiving active aiTBS (n = 21, dof = 18) or sham aiTBS (n = 24, dof = 21), respectively. Note the different statistical thresholds. [Color figure
can be viewed at wileyonlinelibrary.com]
Table 3. Details of the ROI in the Right Isthmus Part of the Cingulate Cortex in Which Changes in CT Are Significantly Correlated With the Direct Clinical
Responses to aiTBS.




ROI (p < 0.01)







Isthmus CC (r) 184 707 3.551 (51,928) 18.7 −48.4 6.3 −0.22, 0.30 −0.60, <0.01 −0.42, <0.01
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vs. females, or when the different depression stages were com-
pared. Correlations between age and baseline thickness were sig-
nificant in the pars opercularis, left precuneus, and the left
posterior cingulate cortex. Changes in cortical thickness in the
right caudal ACC ROI after the first week of stimulation were sta-
tistically different for patient from stage I and II. A full overview of
this assessment can be found in Supporting Information D.
DISCUSSION
This study investigated the relation between cortical thickness
and the clinical response to left dorsolateral prefrontal aiTBS.
Baseline cortical thickness values were correlated with direct
changes in HDRS, measured after four days of stimulation, and
delayed changes, measured during follow-up two weeks after the
end of the cross-over design. Baseline cortical thickness in the left
superior prefrontal gyrus was positively correlated with the direct
clinical response, both for the subjects receiving sham and active
aiTBS. This positive correlation suggests that TRD patients with
“relatively” thicker left prefrontal cortical areas may show better
clinical responses, irrespective of the type of treatment. Acceler-
ated stimulation protocols indeed tend to yield positive clinical
changes not different between active and sham stimulation (7).
Even though the link between cortical thickness and the
responses to brain stimulation treatment has been reported
before (15,27,28), there is currently no full understanding of the
potential underlying physiology. rTMS is thought to induce neuro-
plastic effects, that is, the reorganization of the brain in response
to stimulation (29). Variation in cortical thickness is an example of
potential neuroplastic effects and could reflect differences in glial
cell density (30). Variation in cortical thickness might affect the
distribution of the rTMS-induced electric field within the brain
and thereby influence the effectiveness of the stimulation (27). As
reviewed by Sackeim (28) similar as for electroconvulsive therapy
(ECT), it may be that volumetric changes after rTMS are deter-
mined by multiple processes. Future studies would benefit from
recording structural MRI data at multiple time points to retrieve
information about the temporal changes in cortical thickness after
aiTBS. Additionally, small animal studies could help to gain more
insight in the neuroplastic effects of rTMS, for example, by cou-
nting neuronal cells in cortical regions that are expected to be
affected by this type of neurostimulation.
Nevertheless, the most consistent findings throughout this
study showed that the right caudal part of the cingulate cortex
was the anatomical region implicated in prediction and changes
to aiTBS treatment. First, baseline cortical thickness in the right
cACC was significantly correlated with the direct clinical response
to active aiTBS. Second, longitudinal changes in cortical thickness
between T1 and T2 were significantly correlated with the direct
clinical responses and these changes in thickness showed predic-
tive potential for the delayed clinical effects, measured at T4. The
caudal part of the cingulate cortex has previously been linked to
the response to MDD treatment (11,31,32). Interestingly, using the
8 Figure 8. Relation between ΔCT and ΔHDRSdir for the two ROIs that showed significant (p < 0.01) correlations: right caudal part of the ACC and the right
precuneus. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 7. Overview of ΔCT vs. ΔHDRSdir in the ROI in the right isthmus part
of the cingulate cortex (CC). [Color figure can be viewed at
wileyonlinelibrary.com]
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same dataset, it was shown that indirect structural connections
(derived from diffusion weighted MRI data) between the stimula-
tion site in the left DLPFC and the right cACC was significantly
correlated with the direct clinical responses (11). Moreover, Tik
et al. (33) showed network specific changes in functional connec-
tivity after active but not sham rTMS applied to the left DLPFC in
healthy subjects. This specific network contains the caudal part of
the ACC. After active rTMS, the network showed increased func-
tional connectivity with the ACC. The results of Tik et al. (33) con-
firmed the earlier findings from Fox et al. (8,9); namely that the
functional connectivity between the stimulation site in the left
DLPFC and the subgenual part of the ACC are relevant for rTMS
treatment efficacy for depression subjects. In another functional
connectivity study, including only healthy subjects, it was also
shown that individual resting-state functional connectivity
between left DLPFC and caudal ACC was linked to a larger attenu-
ation of stress-system sensitivity during active, but not during
sham iTBS (34).
Even though the most significant peak of the caudal ACC ROI
for the prediction of the direct clinical response (ROI 8, Fig. 2) is in
the caudal part of the ACC, the total ROI extends within the ros-
tral part (rACC). Specific predictive potential within the right rACC
(volume measures) have been shown for the prediction of cogni-
tive behavioral therapy for depression (35). Moreover, these find-
ings furthermore support the observations of Boes et al. (15), who
showed significant correlations between baseline cortical thick-
ness in the rACC and the clinical responses to standard rTMS,
though on the left side. The subgenual part of the rostral ACC, in
particular the functional connectivity to the DLPFC, has been
linked to rTMS efficacy before (8,9). The most important difference
between this study and the study by Boes et al. is the stimulation
protocol. Whereas Boes et al. studied MDD patients who received
standard daily rTMS treatment administered to the left DLPFC, this
study describes subjects who were enrolled in an aiTBS study.
Given that the mechanisms of action of TMS treatment are not
fully understood (29), it is possible that there are different mecha-
nisms involved in the responses to daily rTMS and aiTBS. As was
speculated before (7,36), the meaningful clinical effects of acceler-
ated stimulation protocols may occur later in time, indicating del-
ayed plasticity (37,38).
Besides our findings for the right cACC, baseline cortical thick-
ness was furthermore positively correlated with the direct clinical
response in the lateral and medial orbitofrontal cortices, the pars
opercularis, and posterior cingulate cortex. Meta-analyses have
shown that these regions have thinner cortical gray matter in
MDD patients compared to healthy subjects (39). Specifically for
treatment response, Järnum et al. (40) showed a thinner posterior
cingulate cortex in a subgroup of nonresponders to antidepres-
sant medication and Martinot et al. (41) showed higher metabolic
activity, as measured with positron emission tomography, in the
orbitofrontal cortices in responders to 10 Hz rTMS treatment for
depression. The longitudinal analysis showed a significant nega-
tive correlation between ΔCT and ΔHDRS in the right temporal
region, indicating that decreases in cortical thickness are linked to
more effective rTMS treatment. Previous work (39) showed
reduced cortical thickness in the temporal lobe in MDD patients
compared to healthy volunteers. Even though normalization
(in this case increase) of altered brain morphology would be
expected with successful treatment, this study showed a signifi-
cant (p < 0.01, uncorrected) negative correlation between the lon-
gitudinal changes in cortical thickness and clinical responses in
the right temporal lobe. Although this seems a counterintuitive
finding, in MDD patients antipsychotic medication was found to
decrease cortical thickness (42). Additionally, Wang et al. (43)
reported temporal cortical volumetric decreases on the long term
after ECT, suggesting that volumetric cortical decreases are not
always related to clinical worsening. One potential explanation for
the rapid decrease of temporoparietal cortical thickness after
aiTBS could be fast neurophysiological changes (44). For instance,
prompt decreases in regional cerebral blood flow (45) and
regional brain metabolism (46) in the temporal lobe were
observed after effective ECT. A relationship between cortical thin-
ning and decreased perfusion was suggested earlier (47,48). Here,
we also want to emphasize that one of the reasons of the devel-
opment of accelerated rTMS paradigms was not only to yield
9
Table 4. Additional Information of the ROIs.




ROI (p < 0.05)
Min t-value X Y Z Correlations and p-values
Sham





Caudal ACC (r) 1 109 −2.012 (25,900) 7.1 20.2 18.6 −0.13, 0.52 0.34, 0.12 0.03, 0.86
Precuneus (r) 1404 3585 3.043 (130,097) 6.0 −58.8 23.6 −0.01, 0.95 −0.53, 0.01 −0.30, 0.05
Figure 9. ROC curve of the predictive value of the direct changes in cortical
thickness in the right caudal part of the cingulate cortex for the delayed clini-
cal responders. The figure is based on the subgroup of patients who received
active aiTBS during the first week of stimulation (n = 21, of which eight
responded at T4).
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faster response but also higher response and remission rates chal-
lenging those of ECT (35).
Correlation between baseline cortical thickness and ΔHDRSdel
did not result in any significant findings. A possible explanation
could be the use of the cross-over design. The endpoint of the
last HDRS measurement, T4, was exactly four weeks after the start
of the experimental protocol for all patients. Depending on the
randomization order, the time laps between active stimulation
and follow-up measurements was two weeks for the patients who
received sham stimulation first (arm A, Fig. 1) or three weeks for
the ones who received active aiTBS first (arm B, Fig. 1).
It was shown in our behavioral results (7) that subjects who
received sham stimulation first also had a significant decrease in HDRS
scores, indicating an important placebo effect. A limitation of our
cross-over design is that only data from T1 and T2 could be used to
study the effect of active aiTBS, without including any placebo biases.
Previous work (49) showed that head motion during MRI acquisition
can affect measures of cortical thickness. Even though a visual quality
check was performed on our data, no specific motion parameters
were taken into account in this study. Especially the results of the lon-
gitudinal analysis can be affected by different motion confounds.
Future studies investigating cortical thickness in relation to the
response to brain stimulation will benefit from collection of subject
motion information during scan acquisition. Furthermore, no accurate
correction for multiple comparison testing was performed which
might increase the risk of type I error. We here feel that a whole brain
exploratory analysis is the right first step since the effects of our spe-
cific accelerated iTBS protocol on cortical thickness have not been
investigated earlier. This first study might lead to more directed future
studies, using a priori hypotheses.
CONCLUSION
This is the first study that investigates the link between cortical
thickness and the response to aiTBS treatment for depression.
Especially the right caudal part of the cingulate cortex could be
an important neuroanatomical structure for the mechanism of
action of aiTBS. Baseline cortical thickness in the right caudal ACC
was significantly correlated with the direct clinical response to
active aiTBS. Also, these direct changes in thickness showed pre-
dictive potential for the delayed clinical effects, as measured dur-
ing follow-up. Our findings may guide future studies, with larger
datasets, to investigate the specific biomarker potential of cortical
thickness to predict the clinical response to aiTBS in more detail.
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COMMENTS
This is an interesting piece that continues to explore the space
between response to brain stimulation and changes in cortical com-
position. It, like others in this emerging area of the literature,
describes important changes as they related to brain regions impli-
cated in mood (and other) elements. While the precise nature of
observed relationships requires further characterization, this study




Repetitive transcranial magnetic stimulation is increasingly used as
a treatment for major depression, and it is helpful for slightly more
than half of patients that do not respond adequately to medications
(1). As pointed out by Baeken and colleagues, rTMS is a treatment
modality that would greatly benefit from biomarkers that can be
used to personalize the treatment parameters. Biomarkers may help
us predict who will respond to a standard rTMS protocol, versus who
may benefit from alternative protocols or other treatment options.
Similarly, having a better understanding of the biological correlates
of effective treatment may inform the underlying mechanisms of
rTMS. In the search for biomarkers of rTMS treatment response in
depression, cortical thickness is relatively understudied compared to
EEG and functional MRI. This article makes an important contribution,
being the first to look at cortical thickness changes in association
with accelerated intermittent theta burst rTMS. The current findings
align with prior results that also implicate cortical thickness of the
anterior cingulate cortex, both as a region that correlates with even-
tual treatment response and as a correlate with actual treatment 11
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response (2). These findings raise a number of interesting questions
that will be important to explore going forward: are the observed
cortical thickness changes unique to rTMS, or do they overlap with
those seen with other treatment modalities? How do these changes
in cortical thickness relate to alterations in functional connectivity pat-
terns or neurotransmitter metabolites? How early are cortical thickness
changes seen, and how long do they last? What cellular or subcellular
processes underlie the observed changes in cortical thickness? This will
be fertile ground for investigation that promises to aid in our under-
standing of TMS and how we can further optimize it as a therapy.
Aaron D. Boes, MD, PhD
Iowa City, IA USA
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